RIVASA 81 MG EC TABLET (DELAYED-RELEASE)

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

ACETYLSALICYLIC ACID

Mevcut itibaren:

LABORATOIRE RIVA INC.

ATC kodu:

B01AC06

INN (International Adı):

ACETYLSALICYLIC ACID

Doz:

81MG

Farmasötik formu:

TABLET (DELAYED-RELEASE)

Kompozisyon:

ACETYLSALICYLIC ACID 81MG

Uygulama yolu:

ORAL

Paketteki üniteler:

1000

Reçete türü:

OTC

Terapötik alanı:

SALICYLATES

Ürün özeti:

Active ingredient group (AIG) number: 0101169013; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2014-02-17

Ürün özellikleri

_RIVASA 81 MG EC - Product Monograph _
_ _
_Page 1 of 44 _
PRODUCT MONOGRAPH
RIVASA 81 MG EC
Acetylsalicylic
Acid Delayed Release Tablets
81 mg
USP
Platelet aggregation inhibitor
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville,
Quebec
J7C 3V4
www.labriva.com
Date of Preparation:
February 17, 2014
Date of Revision:
September 14, 2022
Control Number: 266709
_RIVASA 81 MG EC - Product Monograph _
_ _
_Page 2 of 44 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
INDICATIONS AND CLINICAL USE
........................................................................
3
CONTRAINDICATIONS
............................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................
4
ADVERSE
REACTIONS.............................................................................................
6
DRUG INTERACTIONS
.............................................................................................
7
DOSAGE AND ADMINISTRATION
..........................................................................
9
OVERDOSAGE
.........................................................................................................10
ACTION AND CLINICAL
PHARMACOLOGY.........................................................11
STORAGE AND STABILITY
....................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
..........................................12
PART II: SCIENTIFIC INFORMATION
..........................................................................
13
PHARMACEUTICAL INFORMATION
.....................................................................13
CLINICAL TRIALS
...................................................................................................14
DETAILED
PHARMACOLOGY.........